5-oxo-4,5-dihydroimidazo[1,5-a]quinazoline compounds as pi3k[alpha] inhibitors.

CL202601201A1Pending Publication Date: 2026-07-31PIKAVATION THERAPEUTICS INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202601201
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-10-16
Filing Date: 2026-04-14
Publication Date: 2026-07-31

Application Information

Patent Timeline

16 Oct 2024

Priority

14 Apr 2026

Application

CL202601201

31 Jul 2026

Publication

CL202601201A1

IPC: A61P35/00; A61K31/517; A61K31/519; A61K31/536; C07D487/04; C07D519/00

CPC: C07D487/04; C07D519/00; A61P35/00; A61K31/519

Inventors: QI Chao; ZHOU Fei

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

This application provides tricyclic compounds that modulate PI3K[ALPHA] activity, which are useful in the treatment of various diseases, including cancer.

Need to check novelty before this filing date? Find Prior Art